You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Citation Tools

Article menu

Download PDFPDF

Treatments
Original article
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Curtis JR, Mariette X, Gaujoux-Viala C, et al
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
RMD Open 2019;5:e000942. doi: 10.1136/rmdopen-2019-000942